A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 27 Mar 2019 Status changed from suspended to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2018 Status changed from not yet recruiting to suspended.